NO2768984T3 - - Google Patents

Info

Publication number
NO2768984T3
NO2768984T3 NO12841612A NO12841612A NO2768984T3 NO 2768984 T3 NO2768984 T3 NO 2768984T3 NO 12841612 A NO12841612 A NO 12841612A NO 12841612 A NO12841612 A NO 12841612A NO 2768984 T3 NO2768984 T3 NO 2768984T3
Authority
NO
Norway
Application number
NO12841612A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2768984T3 publication Critical patent/NO2768984T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Insulating Materials (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
NO12841612A 2015-11-12 2012-10-19 NO2768984T3 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562254375P 2015-11-12 2015-11-12

Publications (1)

Publication Number Publication Date
NO2768984T3 true NO2768984T3 (pt) 2018-06-09

Family

ID=57348648

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12841612A NO2768984T3 (pt) 2015-11-12 2012-10-19

Country Status (36)

Country Link
US (2) US10544211B2 (pt)
EP (2) EP3191511B1 (pt)
JP (2) JP6962915B2 (pt)
KR (2) KR102641194B1 (pt)
CN (1) CN108473563B (pt)
AU (2) AU2016352943B2 (pt)
BR (1) BR112018009714A8 (pt)
CA (2) CA3005085A1 (pt)
CL (1) CL2018001291A1 (pt)
CO (1) CO2018005915A2 (pt)
CR (1) CR20180311A (pt)
CY (1) CY1120303T1 (pt)
DK (1) DK3191511T3 (pt)
DO (1) DOP2018000122A (pt)
EC (1) ECSP18042569A (pt)
ES (1) ES2662418T3 (pt)
GT (1) GT201800095A (pt)
HK (1) HK1248716A1 (pt)
HR (1) HRP20171949T1 (pt)
HU (1) HUE035805T2 (pt)
IL (2) IL259269B1 (pt)
LT (1) LT3191511T (pt)
MA (1) MA41653A (pt)
MD (1) MD3191511T2 (pt)
ME (1) ME02954B (pt)
MX (1) MX2018005992A (pt)
NO (1) NO2768984T3 (pt)
PE (1) PE20181317A1 (pt)
PH (1) PH12018501025A1 (pt)
PL (1) PL3191511T3 (pt)
PT (1) PT3191511T (pt)
RS (1) RS56676B1 (pt)
SG (1) SG11201803975SA (pt)
SI (1) SI3191511T1 (pt)
TN (1) TN2018000159A1 (pt)
WO (1) WO2017081320A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
KR102240318B1 (ko) 2011-06-23 2021-04-15 아블린쓰 엔.브이. 면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법
AU2015261536B2 (en) 2014-05-16 2020-05-07 Ablynx Nv Improved immunoglobulin variable domains
NO2768984T3 (pt) * 2015-11-12 2018-06-09
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
AU2020396204A1 (en) 2019-12-06 2022-07-28 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting TNFα and IL-23
MX2022006881A (es) 2019-12-06 2022-07-11 Ablynx Nv Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa y ox40l.
CN112300289B (zh) * 2019-12-30 2022-06-10 中国药科大学 RGD4C融合抗TNFα纳米抗体蛋白、制备方法及其应用
KR20230123497A (ko) 2020-12-18 2023-08-23 아블린쓰 엔.브이. IL-6 및 TNF-α를 표적화하는 면역글로불린 단일 가변도메인을 포함하는 폴리펩티드
WO2024097571A1 (en) * 2022-11-04 2024-05-10 St. Jude Children's Research Hospital, Inc. Nlrp12 and nlrc5 modulators and methods for using the same to modulate diseases

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69330523T4 (de) 1992-08-21 2012-08-23 Vrije Universiteit Brussel Immunoglobuline ohne leichte ketten
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DE69841562D1 (de) 1997-10-27 2010-04-29 Bac Ip Bv Multivalente antigenbindende proteine
JP2003525016A (ja) 1998-02-19 2003-08-26 エクサイト セラピーズ, インコーポレイテッド リンパ球活性化を調節するための組成物および方法
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US20060228355A1 (en) 2003-11-07 2006-10-12 Toon Laeremans Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
CA2505316C (en) 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CA2512545C (en) 2003-01-10 2015-06-30 Karen Silence Recombinant vhh single domain antibody from camelidae against von willebrand factor (vwf)
CN1845938B (zh) 2003-06-30 2010-05-26 杜门蒂斯有限公司 多肽
CA2583017A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
MX2007006593A (es) 2004-12-02 2008-03-04 Domantis Ltd Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
LT2949668T (lt) * 2005-05-18 2019-11-11 Ablynx Nv Pagerinti nanokūnai tm prieš navikų nekrozės faktorių alfa
EP2007814A2 (en) 2005-05-20 2008-12-31 Ablynx N.V. Single domain vhh antibodies against von willebrand factor
DE102005023617A1 (de) * 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
CA2619748C (en) 2005-08-30 2016-06-14 Actogenix Nv Novel treatment of chronic enterocolitis
KR20080077238A (ko) 2005-12-01 2008-08-21 도만티스 리미티드 인터루킨 1 수용체 타입 1에 결합하는 비경쟁적 도메인항체 포맷
CN101466734A (zh) 2005-12-01 2009-06-24 杜门蒂斯有限公司 与白细胞介素-1受体1型结合的竞争性域抗体形式
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
WO2007085814A1 (en) 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2008068280A1 (en) 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
NZ581097A (en) 2007-05-24 2012-03-30 Ablynx Nv Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
US20110053865A1 (en) 2007-11-27 2011-03-03 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
RU2010151725A (ru) 2008-05-16 2012-06-27 Аблинкс Нв (Be) Аминокислотные последовательности, направленные против cхcr4 и других gpcr, и соединения, включаюшие их
CN102405236A (zh) * 2009-02-19 2012-04-04 葛兰素集团有限公司 改进的抗-tnfr1多肽,抗体可变结构域和拮抗剂
NZ595461A (en) 2009-04-10 2013-01-25 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
EP2454285A2 (en) 2009-07-16 2012-05-23 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
AU2012234284B2 (en) 2011-03-28 2015-10-08 Ablynx Nv Bispecific anti-CXCR7 immunoglobulin single variable domains
JP6324887B2 (ja) 2011-06-23 2018-05-16 アブリンクス エン.ヴェー. 血清アルブミンに結合するタンパク質
KR102240318B1 (ko) * 2011-06-23 2021-04-15 아블린쓰 엔.브이. 면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법
EP2744822B1 (en) * 2011-08-17 2020-06-24 Glaxo Group Limited Modified proteins and peptides
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
AU2015261536B2 (en) * 2014-05-16 2020-05-07 Ablynx Nv Improved immunoglobulin variable domains
NO2768984T3 (pt) 2015-11-12 2018-06-09

Also Published As

Publication number Publication date
JP2019506839A (ja) 2019-03-14
MD3191511T2 (ro) 2018-03-31
TN2018000159A1 (en) 2019-10-04
RU2018120524A3 (pt) 2020-09-24
WO2017081320A1 (en) 2017-05-18
MX2018005992A (es) 2019-01-31
GT201800095A (es) 2019-08-15
IL259269B1 (en) 2024-03-01
HRP20171949T1 (hr) 2018-01-26
AU2016352943B2 (en) 2022-10-20
CY1120303T1 (el) 2019-07-10
US20170190769A1 (en) 2017-07-06
SI3191511T1 (en) 2018-01-31
CA3005085A1 (en) 2017-05-18
US9745372B2 (en) 2017-08-29
PE20181317A1 (es) 2018-08-14
IL259269A (en) 2018-07-31
PT3191511T (pt) 2017-11-30
EP3191511B1 (en) 2017-09-20
EP3266798A2 (en) 2018-01-10
ES2662418T3 (es) 2018-04-06
LT3191511T (lt) 2018-01-10
ECSP18042569A (es) 2018-07-31
CR20180311A (es) 2018-10-18
AU2016352943A1 (en) 2018-06-07
IL310373A (en) 2024-03-01
CN108473563B (zh) 2022-06-14
CO2018005915A2 (es) 2018-06-20
HUE035805T2 (en) 2018-05-28
HK1248716A1 (zh) 2018-10-19
BR112018009714A2 (pt) 2018-11-21
AU2023200113A1 (en) 2023-02-16
EP3191511A1 (en) 2017-07-19
DOP2018000122A (es) 2018-09-30
DK3191511T3 (en) 2018-01-08
RU2018120524A (ru) 2019-12-13
RS56676B1 (sr) 2018-03-30
US20170267752A1 (en) 2017-09-21
US10544211B2 (en) 2020-01-28
EP3266798A3 (en) 2018-03-28
KR102641194B1 (ko) 2024-02-26
CN108473563A (zh) 2018-08-31
JP2022020666A (ja) 2022-02-01
KR20240029115A (ko) 2024-03-05
PH12018501025A1 (en) 2019-01-28
JP6962915B2 (ja) 2021-11-10
ME02954B (me) 2018-07-20
CL2018001291A1 (es) 2018-09-14
CA3234178A1 (en) 2017-05-18
BR112018009714A8 (pt) 2019-02-26
JP7357038B2 (ja) 2023-10-05
PL3191511T3 (pl) 2018-03-30
KR20180083382A (ko) 2018-07-20
MA41653A (fr) 2018-01-09
SG11201803975SA (en) 2018-06-28

Similar Documents

Publication Publication Date Title
BR112014017635A2 (pt)
BR112014017614A2 (pt)
BR112014017592A2 (pt)
BR112014017625A2 (pt)
BR112014017659A2 (pt)
BR112014017646A2 (pt)
BR112014017607A2 (pt)
BR112014018031A2 (pt)
BR112013027865A2 (pt)
BR112014017634A2 (pt)
BR112014017609A2 (pt)
BR112014017644A2 (pt)
BR112014017647A2 (pt)
BR112014017588A2 (pt)
BR112014013184A8 (pt)
BR112014018877A2 (pt)
BR112014017652A2 (pt)
BR112014017621A2 (pt)
BR112014017630A2 (pt)
BR112014017622A2 (pt)
BR112014017627A2 (pt)
BR112014017623A2 (pt)
BR112014017641A2 (pt)
NO2768984T3 (pt)
BR112014017631A2 (pt)